<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03658421</url>
  </required_header>
  <id_info>
    <org_study_id>[2018]45</org_study_id>
    <nct_id>NCT03658421</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine as Adjuvant for FNB in TKA</brief_title>
  <official_title>Comparison of Dexmedetomidine as Adjuvant to Different Concentrations of Ropivacaine for Femoral Nerve Blockade in Patients Undergoing Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study was to find out whether addition of dexmedetomidine to lower
      concentration of ropivacaine preoperatively in femoral nerve block (FNB) would intensify
      analgesia and preserve quadriceps muscle strength after TKA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We designed this study to evaluate whether dexmedetomidine added to lower concentration of
      ropivacaine for FNB can intensify analgesic effect and meanwhile reduce the possibility of
      lower limb (or quadriceps) weakness. Three groups were compared: 0.2% ropivacaine (H group),
      0.1% ropivacaine (L group) and ropivacaine 0.1% added with 2 μg/kg dexmedetomidine (LD
      group).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Actual">November 10, 2018</completion_date>
  <primary_completion_date type="Actual">November 5, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of manual muscle testing (MMT) over 72 hours postoperatively</measure>
    <time_frame>0-72 hours postoperatively</time_frame>
    <description>The MMT grading was recorded from 0 to 5 to measure muscle strength at 6, 12, 24, 36, 48 and 72 hours after surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Timed Up and Go test (TUG) over 72 hours postoperatively</measure>
    <time_frame>0-72 hours postoperatively</time_frame>
    <description>TUG test was used to assess the patient's mobility that requires both balance and static. It was measured at 24, 48 and 72 hours after surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of numeric rating scales (NRS) over 72 hours postoperatively</measure>
    <time_frame>0-72 hours postoperatively</time_frame>
    <description>NRS was used to evaluate postoperative pain control. They were measured at 6, 12, 24, 36, 48 and 72 hours after surgery.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Nerve Block</condition>
  <condition>Dexmedetomidine</condition>
  <arm_group>
    <arm_group_label>H group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H group stands for High concentration group. A single bolous of 20 ml ropivacaine 0.2% in ultrasound-guided femoral nerve block (FNB) before the TKA surgery, followed by continuous femoral nerve block (CFNB) using ropivacaine 0.2% (5 ml/h) for postoperative analgesia which started right after surgery. After surgery, all patients received multimodal analgesia of 200mg celecoxib every 12 hours. All subjects received anothother intravenous patient-controlled analgesia pump (IV-PCA pump), which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>L group stands for low concentration group. A single bolous of 20 ml ropivacaine 0.1% in ultrasound-guided femoral nerve block (FNB) before the TKA surgery, followed by continuous femoral nerve block (CFNB) using ropivacaine 0.1% (5 ml/h) for postoperative analgesia which started right after surgery. All subjects received anothother intravenous patient-controlled analgesia pump (IV-PCA pump), which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LD group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LD group stands for low concentration group with dexmedetomidine. A single bolous of 20 ml ropivacaine 0.1% plus 2 μg/kg dexmedetomidine in ultrasound-guided femoral nerve block (FNB) before the TKA surgery, followed by continuous femoral nerve block (CFNB) using ropivacaine 0.1% (5 ml/h) for postoperative analgesia which started right after surgery. All subjects received anothother intravenous patient-controlled analgesia pump (IV-PCA pump), which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine added to lower concentration of ropivacaine for postoperative analgesia in FNB</description>
    <arm_group_label>LD group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ultrasound-guided femoral nerve block</intervention_name>
    <description>ultrasound-guided femoral nerve block, a single bolous of 20 ml ropivacaine (concentration 0.2% for H group or 0.1% for L group) before surgery followed by continuous femoral nerve block using an infusion rate of ropivacaine 0.2% 5 ml/h for postoperative analgesia started right after surgery</description>
    <arm_group_label>H group</arm_group_label>
    <arm_group_label>L group</arm_group_label>
    <arm_group_label>LD group</arm_group_label>
    <other_name>FNB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>intravenous patient-controlled analgesia pump with morphine</intervention_name>
    <description>All subjects received intravenous patient-controlled analgesia (IV-PCA) pumps to measure additional morphine consumption, which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.</description>
    <arm_group_label>H group</arm_group_label>
    <arm_group_label>L group</arm_group_label>
    <arm_group_label>LD group</arm_group_label>
    <other_name>IV-PCA pump</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Continuous femoral nerve block</intervention_name>
    <description>All the continuous femoral nerve block infusion regimes in the pump were connected to CFNB catheter, which contained only ropivacaine with different concentrations (ropivacaine 0.1% for L group and LD group; ropivacaine 0.2% for H group, 5 ml/h).</description>
    <arm_group_label>H group</arm_group_label>
    <arm_group_label>L group</arm_group_label>
    <arm_group_label>LD group</arm_group_label>
    <other_name>CFNB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I-II

          -  scheduled for total knee arthroplasty

        Exclusion Criteria:

          -  refusal to participate in this study

          -  unicompartmental knee arthroplasty

          -  BMI &gt; 35 kg/m2

          -  congnitive or phychiatric history

          -  refusal of general anesthesia

          -  contraindication to laryngeal mask airway insertion

          -  contraindication to peripheral nerve block (localized infections, sepsis,
             coagulopathy, bleeding diathesis or preexisting lower extremity neurological
             abnormality)

          -  allergy to the drugs used
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xia Feng, MD. Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anesthesiology, First affiliated hospital of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Anesthesiology, First affiliated hospital of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Marhofer D, Kettner SC, Marhofer P, Pils S, Weber M, Zeitlinger M. Dexmedetomidine as an adjuvant to ropivacaine prolongs peripheral nerve block: a volunteer study. Br J Anaesth. 2013 Mar;110(3):438-42. doi: 10.1093/bja/aes400. Epub 2012 Nov 15.</citation>
    <PMID>23161360</PMID>
  </reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>September 1, 2018</study_first_submitted>
  <study_first_submitted_qc>September 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <last_update_submitted>November 15, 2018</last_update_submitted>
  <last_update_submitted_qc>November 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Feng Xia</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>femoral nerve blockade</keyword>
  <keyword>dexmedetomidine</keyword>
  <keyword>ropivacaine</keyword>
  <keyword>anesthesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

